Weiss Ratings Reaffirms Sell (D-) Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “sell (d-)” rating reaffirmed by Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Other analysts have also issued research reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Wednesday, October 15th. HC Wainwright boosted their price objective on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. WBB Securities reissued a “strong-buy” rating and issued a $45.00 price objective on shares of Omeros in a research report on Wednesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. Finally, Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.50.

Omeros Stock Performance

Shares of OMER opened at $7.55 on Friday. The firm’s 50 day moving average price is $4.93 and its two-hundred day moving average price is $4.56. The firm has a market cap of $513.85 million, a P/E ratio of -3.58 and a beta of 2.32. Omeros has a twelve month low of $2.95 and a twelve month high of $13.60.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. On average, sell-side analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omeros

Several large investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Omeros in the first quarter valued at about $579,000. Hsbc Holdings PLC acquired a new position in shares of Omeros in the first quarter valued at about $142,000. Nuveen LLC acquired a new position in shares of Omeros in the first quarter valued at about $938,000. Wellington Management Group LLP acquired a new position in shares of Omeros in the first quarter valued at about $1,118,000. Finally, Invesco Ltd. grew its stake in shares of Omeros by 169.1% in the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after acquiring an additional 54,696 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.